MedTrace Logo

Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients

NCT03324945 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2020-11-12

No results posted yet for this study

Summary

Chemotherapy-induced cognitive impairment (CICI), also known as "chemobrain," is a spectrum of neurocognitive deficits experienced during and after the administration of chemotherapy for cancer. The incidence of CICI is significant, affecting anywhere from 25 to 75% of survivors, and the biologic basis is unknown. This novel study is designed to address the questions of incidence and biological cause for CICI, while gaining a better understanding of the structural and functional effects of chemotherapy on the brain.

Conditions

  • Chemotherapy-induced Cognitive Impairment

Interventions

BEHAVIORAL

Neurocognitive assessments

Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)

Sponsors & Collaborators

  • Office of US Army Medical Research and Material Command

    collaborator UNKNOWN

  • Rachel Miller

    lead OTHER

Principal Investigators

  • Rachel W Miller, MD · University of Kentucky

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-01
Primary Completion
2018-10-12
Completion
2019-04-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03324945 on ClinicalTrials.gov